| Ms Angela Y Wo, MD | |
|
2901 Transport St Se, Albuquerque, NM 87106-4382 | |
| (505) 262-7097 | |
| (505) 262-7636 |
| Full Name | Ms Angela Y Wo |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 24 Years |
| Location | 2901 Transport St Se, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114976610 | NPI | - | NPPES |
| 26257301 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 25MA07980200 (New Jersey) | Secondary |
| 207N00000X | Dermatology | MD2012-0043 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine General Medical Center | Augusta, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainegeneral Medical Center | 1254245715 | 487 |
News Archive
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.
The last few years have seen a puzzling and welcome new trend in health care spending: Instead of going up and up, increases have slowed way down.
Murad, Inc. announced it has tripled the size of its product development department to meet escalating demand for support functions sparked by the growing pipeline of innovative products created when Jeff Murad, Vice President of Product Development for Murad, joined the development team.
Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.
The U.S. government continues to lay the groundwork for efforts under the U.S. Global Health Initiative (GHI), announcing the first round of "GHI Plus" countries, as well as the program's governance structure. GHI is a six-year, $63 billion initiative to help partner countries improve measurable health outcomes by strengthening health systems and building upon proven results. It places a particular focus on improving the health of women, newborns and children.
› Verified 6 days ago
| Entity Name | Mainegeneral Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669423380 PECOS PAC ID: 1254245715 Enrollment ID: O20031118000718 |
News Archive
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.
The last few years have seen a puzzling and welcome new trend in health care spending: Instead of going up and up, increases have slowed way down.
Murad, Inc. announced it has tripled the size of its product development department to meet escalating demand for support functions sparked by the growing pipeline of innovative products created when Jeff Murad, Vice President of Product Development for Murad, joined the development team.
Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.
The U.S. government continues to lay the groundwork for efforts under the U.S. Global Health Initiative (GHI), announcing the first round of "GHI Plus" countries, as well as the program's governance structure. GHI is a six-year, $63 billion initiative to help partner countries improve measurable health outcomes by strengthening health systems and building upon proven results. It places a particular focus on improving the health of women, newborns and children.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Angela Y Wo, MD Po Box 26028, Albuquerque, NM 87125-6028 Ph: (505) 232-1617 | Ms Angela Y Wo, MD 2901 Transport St Se, Albuquerque, NM 87106-4382 Ph: (505) 262-7097 |
News Archive
Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.
The last few years have seen a puzzling and welcome new trend in health care spending: Instead of going up and up, increases have slowed way down.
Murad, Inc. announced it has tripled the size of its product development department to meet escalating demand for support functions sparked by the growing pipeline of innovative products created when Jeff Murad, Vice President of Product Development for Murad, joined the development team.
Dendreon Corporation today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Monday, June 7 at 8:00 a.m. CT.
The U.S. government continues to lay the groundwork for efforts under the U.S. Global Health Initiative (GHI), announcing the first round of "GHI Plus" countries, as well as the program's governance structure. GHI is a six-year, $63 billion initiative to help partner countries improve measurable health outcomes by strengthening health systems and building upon proven results. It places a particular focus on improving the health of women, newborns and children.
› Verified 6 days ago
Dr. Willliam F Willis, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 7520 Montgomery Blvd Ne, Albuquerque, NM 87109 Phone: 505-884-7070 Fax: 505-884-6018 | |
R. Steven Padilla, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1021 Medical Arts Ave Ne, Albuquerque, NM 87102 Phone: 505-272-4947 | |
Phillip Strange, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1021 Medical Arts Ave Ne, Msc09 4240, Albuquerque, NM 87102 Phone: 505-272-6222 | |
Carol Purcell, PA-C Dermatology Medicare: Accepting Medicare Assignments Practice Location: 10151 Montgomery Blvd Ne Bldg 1, Suite A, Albuquerque, NM 87111 Phone: 505-855-5503 Fax: 505-855-5533 | |
Dr. Heidi Elizabeth Fleischmann, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 7520 Montgomery Blvd Ne, Bldg D4, Albuquerque, NM 87109 Phone: 505-884-7070 Fax: 505-884-6018 | |
Dr. Emily M Altman, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 933 Bradbury Dr Se Ste 2222, Albuquerque, NM 87106 Phone: 505-272-6000 Fax: 505-272-6228 | |
Shelly Ann Stepenaskie, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1001 Woodward Pl Ne, Albuquerque, NM 87102 Phone: 505-938-8296 Fax: 505-938-8688 |